Investigators noted the importance of improving educational efforts about the safety and efficacy of matched sibling donor HSCT for children with sickle cell disease.
The FDA has accepted for filing and granted Priority Review to narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.
Investigators discussed their clinical approaches to the diagnosis and management of malignant infantile osteopetrosis, as well as the management of long-term posttrasnplant complications.
Among patients receiving allogeneic stem cell transplantation, high levels of vitamin E may be linked to less acute graft-vs-host disease.
Experts assessed mortality rates linked to allogeneic stem cell transplantation in the past 40 years using data from the European Society for Blood and Marrow Transplantation registry.
For patients with sickle cell disease, HSCT may not be associated with a significant increase in CKD incidence or prevalence following transplantation.
Among patients with blood cancers, genetic variant profiles may negatively affect allo-HSCT outcomes including leukemia-free survival and acute GVHD.
A study aimed to define the benefit of HSCT over non-HSCT therapy in older patients with myelodysplastic syndrome.
